BVS vs VRTX: fair value comparison
Bioventus Inc. and Vertex Pharmaceuticals Incorporated · Updated 2026-08-31
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, VRTX currently sits closer to the top of our discount ranking. VRTX carries the stronger quality grade.
| BVS | VRTX | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $13.47 | $541.69 |
| 12-month range | $6.56–$13.47 | $401.00–$486.03 |
| Sector rank | #86 of 113 Healthcare | #81 of 113 Healthcare |
| Quality grade | D | A |
| Momentum grade | B | B |
| Leverage | Moderate | Low |
| Margin trend | — | Stable |
| Revenue growth | — | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BVS fair value analysis · VRTX fair value analysis